From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Globus Medical, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor ...

Globus Medical (NYSE:GMED – Get Free Report)‘s stock had its “hold” rating restated by equities researchers at Needham & ...

Globus Medical (NYSE:GMED – Get Free Report) had its target price dropped by investment analysts at Truist Financial from $90.00 to $82.00 in a research note issued to investors on Tuesday,Benzinga ...

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

According to Benzinga Pro, Globus Medical's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers. Did you ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.